Frontier Medicines

Frontier Medicines is a biotechnology company based in South San Francisco, specializing in the development of precision medicines for genetically defined patient populations. The company operates in the biopharmaceutical market, focusing on oncology and other hard-to-treat diseases. Frontier Medicines employs cutting-edge technologies such as chemoproteomics, covalent drug discovery, and machine learning to identify and develop small molecule interventions against otherwise undruggable disease-causing targets. Their business model revolves around the discovery and development of proprietary drug candidates, which they advance through clinical trials and eventually commercialize. Revenue is generated through the sale of these novel therapeutics, as well as potential partnerships and licensing agreements with larger pharmaceutical companies. The company's lead program, FMC 376, is a novel dual inhibitor targeting both active and inactive KRAS G12C, a mutation commonly found in cancer. Frontier Medicines has also developed the AutoTAC platform, a novel approach to targeted protein degradation, which aims to simplify and accelerate the drug development process. This platform has the potential to address a wide range of pathological agents, including large protein aggregates, damaged organelles, viruses, and bacteria.

Keywords: biotechnology, precision medicines, chemoproteomics, oncology, machine learning, covalent drug discovery, AutoTAC, KRAS G12C, protein degradation, biopharmaceutical.